U.S. NIH study shows highest efficacy from J&J vaccine + Moderna booster shot combination
Updated: 2021-10-14 17:01:43 KST
The U.S. National Institutes of Health has released data from a study of more than 450 people who have received a full COVID-19 vaccine regimen from Pfizer, Moderna, or Johnson&Johnson.
These participants were divided into groups and given either an extra shot of their original vaccine or a booster shot from a different company. Efficacy of the booster shot was measured by their antibody levels at two weeks and four weeks.
Researchers found that people who originally received the single-dose of Johnson and Johnson's Janssen vaccine produced the strongest antibody levels after receiving a Moderna booster shot. This group showed antibody levels rising 76 times in the first 15 days.
Those who had the Janssen vaccine followed by a Pfizer booster shot saw their antibody levels increase by 35 times, and those who had a second Janssen shot saw antibody levels just four times higher than before.
Researchers have reported that the side-effects of the booster shot were similar to the original vaccinations such as pain around the injection site, malaise, headaches and muscle pain.
Findings of this "Mix and Match Study" will be presented to the Food and Drug Administration advisory committee on Friday at a meeting where they will discuss the authorization of the Moderna and Johnson&Johnson vaccines as booster shots.
The only booster shot that has been approved so far in the U.S. is Pfizer's mRNA vaccine, restricted only to those who have been vaccinated with the Pfizer vaccine. The Centers for Disease Control and Prevention currently does not recommend mixing vaccines.
Lee Eunjin, Arirang News.